Baseline characteristics
| Characteristic . | All patients, N (%) . |
|---|---|
| Median age (y) | 63 |
| IPI score | |
| <3 | 65 (55) |
| ≥3 | 49 (42) |
| Unknown | 3 (3) |
| Classification | |
| DLBCL | 95 (81) |
| HGBL | 22 (19) |
| Prior indolent lymphoma | |
| No | 100 (85) |
| Yes | 17 (15) |
| Cell of origin | |
| Nongerminal center | 58 (50) |
| Germinal center | 58 (50) |
| Indeterminate | 1 (0) |
| MYC rearrangement (n = 111) | |
| No | 88 (75) |
| Yes | 23 (20) |
| Double-hit lymphoma (n = 112) | |
| No | 101 (86) |
| Yes | 11 (9) |
| TP53 mutation | |
| No | 75 (64) |
| Yes | 42 (36) |
| SOCS1 mutation | |
| No | 88 (75) |
| Yes | 29 (25) |
| B2M mutation | |
| No | 93 (79) |
| Yes | 24 (21) |
| CREBBP mutation | |
| No | 94 (80) |
| Yes | 23 (20) |
| TNFRSF14 mutation | |
| No | 97 (83) |
| Yes | 20 (17) |
| TBL1XR1 mutation (n = 62) | |
| No | 52 (84) |
| Yes | 10 (16) |
| GNA13 mutation | |
| No | 100 (85) |
| Yes | 17 (15) |
| MYC mutation (n = 62) | |
| No | 54 (87) |
| Yes | 8 (13) |
| CIITA mutation | |
| No | 103 (88) |
| Yes | 14 (12) |
| DICER1 mutation (n = 62) | |
| No | 55 (89) |
| Yes | 7 (11) |
| BCL2 mutation (n = 62) | |
| No | 55 (89) |
| Yes | 7 (11) |
| EZH2 mutation | |
| No | 104 (89) |
| Yes | 13 (11) |
| ATM mutation | |
| No | 104 (89) |
| Yes | 13 (11) |
| TNFAIP3 mutation | |
| No | 105 (90) |
| Yes | 12 (10) |
| CARD11 mutation | |
| No | 105 (90) |
| Yes | 12 (10) |
| Genetic subtype based on LymphGen | |
| Other | 82 (70) |
| EZB | 26 (22) |
| MCD | 5 (4) |
| ST2 | 5 (4) |
| Characteristic . | All patients, N (%) . |
|---|---|
| Median age (y) | 63 |
| IPI score | |
| <3 | 65 (55) |
| ≥3 | 49 (42) |
| Unknown | 3 (3) |
| Classification | |
| DLBCL | 95 (81) |
| HGBL | 22 (19) |
| Prior indolent lymphoma | |
| No | 100 (85) |
| Yes | 17 (15) |
| Cell of origin | |
| Nongerminal center | 58 (50) |
| Germinal center | 58 (50) |
| Indeterminate | 1 (0) |
| MYC rearrangement (n = 111) | |
| No | 88 (75) |
| Yes | 23 (20) |
| Double-hit lymphoma (n = 112) | |
| No | 101 (86) |
| Yes | 11 (9) |
| TP53 mutation | |
| No | 75 (64) |
| Yes | 42 (36) |
| SOCS1 mutation | |
| No | 88 (75) |
| Yes | 29 (25) |
| B2M mutation | |
| No | 93 (79) |
| Yes | 24 (21) |
| CREBBP mutation | |
| No | 94 (80) |
| Yes | 23 (20) |
| TNFRSF14 mutation | |
| No | 97 (83) |
| Yes | 20 (17) |
| TBL1XR1 mutation (n = 62) | |
| No | 52 (84) |
| Yes | 10 (16) |
| GNA13 mutation | |
| No | 100 (85) |
| Yes | 17 (15) |
| MYC mutation (n = 62) | |
| No | 54 (87) |
| Yes | 8 (13) |
| CIITA mutation | |
| No | 103 (88) |
| Yes | 14 (12) |
| DICER1 mutation (n = 62) | |
| No | 55 (89) |
| Yes | 7 (11) |
| BCL2 mutation (n = 62) | |
| No | 55 (89) |
| Yes | 7 (11) |
| EZH2 mutation | |
| No | 104 (89) |
| Yes | 13 (11) |
| ATM mutation | |
| No | 104 (89) |
| Yes | 13 (11) |
| TNFAIP3 mutation | |
| No | 105 (90) |
| Yes | 12 (10) |
| CARD11 mutation | |
| No | 105 (90) |
| Yes | 12 (10) |
| Genetic subtype based on LymphGen | |
| Other | 82 (70) |
| EZB | 26 (22) |
| MCD | 5 (4) |
| ST2 | 5 (4) |